Albion Financial Group’s Fate Therapeutics FATE Stock Holding History

Albion Financial Group’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$534	Hold	225	–	–	﹤0.01%	690
2026 Q2	$608	Hold	225	–	–	﹤0.01%	606
2026 Q1	$270	Hold	225	–	–	﹤0.01%	705
2025 Q4	$222	Hold	225	–	–	﹤0.01%	629
2025 Q3	$284	Hold	225	–	–	﹤0.01%	626
2025 Q2	$252	Hold	225	–	–	﹤0.01%	561
2025 Q1	$178	Hold	225	–	–	﹤0.01%	582
2024 Q4	$372	Hold	225	–	–	﹤0.01%	646
2024 Q3	$788	Hold	225	–	–	﹤0.01%	465
2024 Q2	$738	Hold	225	–	–	﹤0.01%	468
2024 Q1	$1.65K	Hold	225	–	–	﹤0.01%	426
2023 Q4	$842	Hold	225	–	–	﹤0.01%	435
2023 Q3	$477	Hold	225	–	–	﹤0.01%	444
2023 Q2	$1.07K	Hold	225	–	–	﹤0.01%	413
2023 Q1	$1.28K	Hold	225	–	–	﹤0.01%	390
2022 Q4	$2.27K	Hold	225	–	–	﹤0.01%	377
2022 Q3	$5K	Hold	225	–	–	﹤0.01%	344
2022 Q2	$6K	Hold	225	–	–	﹤0.01%	342
2022 Q1	$9K	Hold	225	–	–	﹤0.01%	370
2021 Q4	$13K	Buy	225 +35	+18%	+$1.98K	﹤0.01%	390
2021 Q3	$11K	Hold	190	–	–	﹤0.01%	362
2021 Q2	$16K	Buy	+190	New	+$15.3K	﹤0.01%	348
2020 Q4	$13K	Buy	+140	New	+$8.69K	﹤0.01%	334

Other funds holding FATE

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Albion Financial Group's FATE Position: Q3 2026 in Review

Albion Financial Group held its Fate Therapeutics (FATE) position steady in Q3 2026 at 225 shares worth $534. The position accounts for ﹤0.01% of the portfolio, ranked #690.

Albion Financial Group first reported a position in FATE in Q4 2020 and has held it in 23 quarters since. The position peaked at $16K in Q2 2021. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

Albion Financial Group held 225 shares of Fate Therapeutics worth $534 as of Q3 2026.
Albion Financial Group left its Fate Therapeutics share count unchanged in Q3 2026.
Fate Therapeutics made up ﹤0.01% of Albion Financial Group's portfolio in Q3 2026, its #690 holding.
Albion Financial Group first reported a position in Fate Therapeutics in Q4 2020 and has held it in 23 quarters since.
Albion Financial Group's Fate Therapeutics position peaked at $16K in Q2 2021.
101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Albion Financial Group's 13F filing for Q3 2026, filed 21 Oct 2026.